deaths (OS)

mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population

versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU 1 0.83 [0.70; 0.99], 1 RCT, I2=0%
unassessable degree of certainty